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An Inside Job: Hacking into Janus Kinase/Signal Transducer and
Activator of Transcription Signaling Cascades by the Intracellular
Protozoan Toxoplasma gondii
Eric Y. Denkers,a David J. Bzik,b Barbara A. Fox,b and Barbara A. Butchera
Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA,a and Department of Microbiology and
Immunology, Dartmouth Medical School, Lebanon, New Hampshire, USAb
The intracellular protozoan Toxoplasma gondii is well known for its skill at invading and living within host cells. New discover-
ies are now also revealing the astounding ability of the parasite to inject effector proteins into the cytoplasm to seize control of
the host cell. This review summarizes recent advances in our understanding of one such secretory protein called ROP16. This
molecule is released from rhoptries into the host cell during invasion. The ROP16 molecule acts as a kinase, directly activating
both signal transducer and activator of transcription 3 (STAT3) and STAT6 signaling pathways. In macrophages, an important
and preferential target cell of parasite infection, the injection of ROP16 has multiple consequences, including downregulation of
proinflammatory cytokine signaling and macrophage deviation to an alternatively activated phenotype.
Intracellular microorganisms, whether bacterial, fungal, or pro-tozoal, are faced with special challenges to achieve a productive
infection. They must survive in a potentially hostile intracellular
environment, and to do so they employ strategies of host evasion,
active interference with host cell machinery, or a combination of
both. The payoff of this high-risk intracellular lifestyle is that the
microorganism gains access to the nutrient-rich environment of
the host cytosol and at the same time avoids extracellular effectors
of host immunity. Unraveling how intracellular pathogens
achieve this intracellular ecological niche is not only fascinating
from a purely biological perspective but can also provide us with
new targets to control infection. In addition, understanding
mechanisms developed by intracellular pathogens to manipulate
the host cell internal environment may provide new insights into
controlling mammalian cell behavior.
Nowhere is this more the case than for the apicomplexan pro-
tozoan Toxoplasma gondii, a parasite that has emerged in recent
years as the model obligate intracellular eukaryotic pathogen.
Toxoplasma is transmitted by ingestion of infectious cysts as a
result of carnivorism or predation. In the intestine of cats, T. gon-
dii undergoes sexual reproduction, resulting in fecal shedding of
highly infectious oocysts (22). While normally asymptomatic,
Toxoplasma may cause severe disease in immunocompromised
populations and during congenital infection (63). The astonish-
ingly widespread geographical and biological distribution of T.
gondii is a dramatic indication of the success of this parasite in
living with its host and achieving successful transmission to new
hosts.
Toxoplasma tachyzoites (the rapidly replicating form of the
parasite responsible for acute toxoplasmosis) enter host cells
through a well-studied process of active invasion involving para-
site actin-based motility and establishment of a moving junction
at the interface between host and parasite membranes (57, 77, 85).
During invasion, the parasite creates a specialized parasito-
phorous vacuole that resists acidification and lysosomal fusion
(58). The vacuole membrane consists of parasite and host lipids
and a subset of parasite proteins but is largely devoid of host cell
proteins (57, 80). The parasitophorous vacuole membrane (PVM)
serves as a molecular sieve through which T. gondii scavenges host
cell nutrients, including certain amino acids, nucleic acid precur-
sors, and lipids, such as cholesterol (12, 16, 24, 25, 74). During
invasion and creation of the PVM, apically oriented organelles
(hence the term “apicomplexan” for this group of protozoa) called
micronemes and rhoptries are discharged, followed later by re-
lease of dense granules (11, 35). Regulated secretion of parasite
proteins originating from these organelles mediates adhesion, in-
vasion, and creation of the mature PVM. Of direct relevance to the
present review, it is also now clear that some of these secreted
molecules are injected directly into the host cell cytoplasm during
invasion (32). Moreover, some injected parasite molecules are di-
rected to the host cell nucleus (6, 31). One of these parasite pro-
teins is ROP16, a specialized kinase that hacks into host cell sig-
naling cascades to modify the behavior of the parasite-infected
host cell (71).
Contained within the parasitophorous vacuole, Toxoplasma
evades elimination by the immune system. The parasite actively
deploys an infection strategy that keeps the host alive to allow
establishment of long-lasting latent infection, promoting the like-
lihood of transmission to new hosts. The latent phase of infection
is characterized by the formation of quiescent cysts in the brain
and skeletal muscle tissue. To prevent host death, T. gondii triggers
a robust Th1 response characterized by early interleukin 12 (IL-
12) production by cells, such as macrophages, dendritic cells
(DC), and neutrophils (5, 29, 67). Early IL-12 production is fol-
lowed by emergence of gamma interferon (IFN-)-producing
CD4 and CD8 T lymphocytes, and these cell types are required
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for surviving acute infection and ultimately preventing potentially
lethal reactivation events during chronic infection (20, 26, 28, 82).
Both IL-12 and IFN- production are essential for the host to
survive infection (72, 73, 81). Absence of either cytokine results in
the inability to control parasite replication and dissemination, re-
sulting in massive tissue necrosis and host death. Yet, parasite-
induced production of both IL-12 and IFN- must also be tightly
regulated to prevent cytokine-mediated mortality (the so-called
“cytokine storm”). Control of these proinflammatory mediators
is achieved initially by direct parasite-mediated suppression (fur-
ther detailed below) and later by induction of anti-inflammatory
cytokines such as IL-10. Evidence for the importance of the latter
cytokine was revealed by now classic studies demonstrating that
without IL-10, mice rapidly succumb to Toxoplasma infection as a
result of dysregulated proinflammatory cytokines rather than loss
of an ability to control the parasite itself (30, 83).
Recent years have witnessed the identification of several Toxo-
plasma effector molecules that directly interact with cells of the
immune system to mediate many of the effects described above
(Table 1). Early reports suggested a role for parasite cyclophilin-18
interacting with chemokine receptor CCR5 to induce IL-12 (1).
This was followed by identification of Toxoplasma profilin as a
ligand for Toll-like receptor 11 (TLR11) driving DC IL-12 induc-
tion (90). Recently, release of dense granule protein GRA15 into
the host cell cytoplasm was found to mediate NF-B activation
and initiate IL-12 synthesis (69). The rhoptry kinase ROP18 was
identified as a virulence determinant that phosphorylates and de-
activates host immunity-related p47 GTPase (IRG) proteins that
mediate IFN--dependent destruction of the PVM (23, 79). A
rhoptry pseudokinase, ROP5, is a major virulence determinant,
although the host target molecule is not yet known (3, 65). Simi-
larly, ROP38 has been identified as a rhoptry protein influencing
host cell signaling (62). Finally, the ROP16 kinase is another de-
terminant of virulence (71). As we review here, the ROP16 mole-
cule is highly complex, because it directly activates at least two
distinct transcription factors in the classical Janus kinase (JAK)/
signal transducer and activator of transcription (STAT) cytokine
signaling pathway.
LINKING TOXOPLASMA-DEPENDENT IMMUNOSUPPRESSION
TO STAT3 ACTIVATION AND FUNCTION
Although T. gondii is known for its ability to infect diverse host cell
types, macrophages, DC, and neutrophils, major effectors of in-
nate immunity, are preferentially targeted during in vivo infection
(4, 14, 17). This is of keen biological interest, because these cell
types are well known for their ability to produce cytokines and
proinflammatory antimicrobial effector molecules. How does
Toxoplasma survive within these masters of antimicrobial de-
fense? Groundbreaking advances in recent years are for the first
time yielding fascinating molecular insight into how this eukary-
otic parasitic pathogen lives within these cells. In particular, Tox-
oplasma seizes control of intracellular signaling pathways during
invasion, specifically those transduction pathways involved in the
JAK/STAT pathway of cytokine production.
While in vivo infection stimulates strong type 1 cytokine-based
immunity in the host, closer examination of the response unex-
pectedly reveals another side to this host-parasite interaction. For
example, from within the infected cell, the parasite efficiently
blocks TLR-linked signaling pathways that originate via extracel-
lular signals, such as lipopolysaccharide (LPS) (9, 21, 43). Simi-
larly, parasite-infected cells become largely nonresponsive to
IFN- activation (39, 40, 50). This results in their defective ability
to activate T cells (51). DC infected with Toxoplasma are also
nonresponsive to TLR activation, and cells are likewise defective
in T cell activation (56). Importantly, DC targeted for infection in
vivo are also nonresponsive to ex vivo TLR activation (4). Early on,
it was recognized that suppression of host responses by T. gondii
required live parasites and an ability to actively invade host cells
(7). The studies collectively suggest that Toxoplasma has devel-
oped mechanisms to downregulate antimicrobial effector mecha-
nisms despite (or perhaps because of) being immersed in an over-
whelmingly proinflammatory cytokine environment. Many
different mechanisms have been proposed to explain these down-
regulatory effects. These include inhibition of NF-B and STAT1
nuclear translocation (9, 52, 76), degradation of STAT1 (92), in-
hibition of mitogen-activated protein kinase (MAPK) signaling
(37), induction of suppressor of eytokine synthesis-1 (SOCS1)
(92), and most recently interference with chromatin remodeling
(45, 46). While each of these phenomena may indeed contribute
to parasite-mediated suppression, a unifying mechanism of sup-
pression is not apparent.
Insight into how Toxoplasma interferes with host signal trans-
duction came from the observation that the parasite triggers rapid,
strong, and sustained activation of STAT3 during infection (10).
The response requires live parasites and is restricted to infected
cells rather than noninfected bystander cells. Importantly, the
ability of T. gondii to mediate suppression of TLR responsiveness
in STAT3-null macrophages was severely curtailed, suggesting
that the parasite actively exploits this transcription factor to in-
hibit proinflammatory responses.
As a member of the JAK/STAT signaling family, the canonical
model of STAT3 function is that cytokines such as IL-10 and IL-6
bind to their heterodimeric receptors, resulting in tyrosine phos-
phorylation of receptor-associated JAK kinases, in turn resulting
in STAT3 recruitment (66). After JAK-dependent STAT3 tyrosine
TABLE 1 Toxoplasma molecules that interact with components of host defense
Parasite molecule Host target/ligand Major effect on host Reference(s)
Profilin TLR11 Induction of IL-12 90
Cyclophilin-18 CCR5 Induction of IL-12 1
GPI moeities TLR2, TLR4 Induction of IL-12, TNF- 19
ROP16 STAT3, STAT6 IL-12 downregulation, arginase 1 induction 8, 36, 61, 71, 89
ROP18 IRG proteins, ATF6 PVM destruction, promotion of CD8 responses 23, 79
ROP5 Unknown Contributes to virulence 3, 65
ROP38 Unknown Suppression of MAPK signaling 62
GRA15 NF-B IL-12 induction 36, 69
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phosphorylation, STAT3 dimerizes and translocates to the nu-
cleus as a functional transcription factor. Full activation of STAT3
and other STAT molecules also requires MAPK-mediated serine
phosphorylation. Nevertheless, this model JAK/STAT pathway
has also been called into question, and alternate models involving
constitutive shuttling of STAT between the nucleus and cytoplasm
have been recently proposed (75).
The effects of STAT3 activation are complex. On the one hand,
IL-10 activation of STAT3 leads to anti-inflammatory responses
and attenuation of cytokines such as tumor necrosis factor alpha
(TNF-) in response to LPS (41, 84). On the other hand, IL-6, a
proinflammatory cytokine that triggers the acute-phase response,
also acts though activation of STAT3 (2). What determines
whether STAT3 is a pro- or anti-inflammatory transcription fac-
tor depends upon the activity of suppressor of cytokine synthesis 3
(SOCS3) during IL-6 signaling (18, 42, 91). Thus, in the absence of
SOCS3, IL-6-stimulated STAT3 activation is prolonged and the
cytokine acts like IL-10 and downregulates TNF- and IL-12. Be-
cause the suppression of proinflammatory responses mediated by
T. gondii is dependent on STAT3 and parasite invasion, the para-
site appears to be exploiting the IL-10 signaling pathway. Never-
theless, it was recently found that parasite-induced STAT3 activa-
tion is enhanced in the absence of SOCS3 in a manner similar to
that of IL-6 (86). The implication of this interesting result is that
there is additional complexity to Toxoplasma-mediated STAT3
activation that we have yet to understand.
RHOPTRY PROTEIN ROP16 ACTIVATES STAT3 AND STAT6
In Europe and North America, Toxoplasma occurs predominantly
as 3 clonal lineages (types I, II, and III) that display differences in
disease pathogenesis in humans and animals (78). Thus, type I
strains are highly virulent in mice, whereas types II and III are
considerably less virulent and cause less pathology during infec-
tion. The stage was set for a major leap in understanding
Toxoplasma-host cell interactions by the observation that type II
but not type I or type III parasite strains triggered large amounts of
macrophage IL-12 and that this was accompanied by strain-
specific translocation of NF-B (38, 68). By genetic examination
of F1 progeny between type II and type III parasite strains, viru-
lence loci were identified, and in this way several secretory rhoptry
proteins emerged as important parasite effectors that controlled
virulence (6). In particular, ROP16 was identified as a virulence
determinant, and pathway analysis suggested that interaction with
STAT signaling was required for the activity of this rhoptry pro-
tein (70, 71). Type I and type III ROP16 were found to be involved
in activation of both STAT3 and STAT6, whereas type II ROP16
was defective in this regard. The tyrosine and serine phosphoryla-
tion stimulated by ROP16 occur on the same amino acid residues
as that induced by cytokine-mediated signaling.
The ROP16 molecule contains a nuclear localization sequence
(NLS), and during invasion it is injected into the host cell cyto-
plasm followed by rapid translocation into the nucleus. As such,
ROP16 is one of a growing number of rhoptry proteins and dense
granule molecules now known to gain access to the intracellular
environment during invasion. The exact mechanism by which
ROP16 is introduced into the host cytoplasm is not known. Al-
though ROP16 contains an NLS which is required for ROP16 to
enter the nucleus, NLS-mutated ROP16 is still capable of activat-
ing STAT6 and also probably STAT3, suggesting that this rhoptry
molecule acts in the cytoplasm to phosphorylate STAT proteins
(71). This raises the interesting possibility that ROP16 may also
possess STAT3- and STAT6-independent activities that provide
additional functions within the host nucleus.
The ROP16 protein was originally identified as a putative
serine-threonine kinase, but more recently it was shown by in vitro
assays to directly tyrosine phosphorylate STAT3 and STAT6 (61,
89). Parenthetically, the recent observation that virus and nucleic
acids activate STAT molecules through endoplasmic reticulum
IFN stimulator (ERIS or STING)-dependent recruitment to the
endoplasmic reticulum provides another possible model for
STAT3 and STAT6 activation by ROP16 (13). Consistent with the
role of STAT3 in downregulating proinflammatory signaling,
ROP16 knockout parasites induce larger amounts of IL-12 than
wild-type parasites, and cells infected with ROP16 knockout par-
asites display a markedly reduced ability to suppress cellular re-
sponses triggered by LPS and IFN- (8).
Interestingly, using ROP16 knockout parasites, we found that
immediate-early activation of STAT3 was normal in the absence
of ROP16, but sustained phosphorylation of STAT3 required this
rhoptry protein (8). In contrast, activation of STAT6 was com-
pletely dependent upon ROP16. The parasite or host molecules
required for the immediate-early ROP16-independent STAT3 ac-
tivation are not currently known. Although inhibitors of JAK sig-
naling can block the immediate-early STAT3 response, interpre-
tation of this result is difficult, because such inhibitors may also act
on parasite kinases (61). Regardless, the observation that the ki-
netics of ROP16-dependent STAT3 and STAT6 activation are not
directly parallel is further indication of the complexity of this
rhoptry protein in the host-parasite interaction.
ROLE OF ROP16-DEPENDENT STAT6 ACTIVATION
Activation of STAT6 is normally associated with signaling driven
by IL-4 or IL-13. In macrophages, this can lead to an M2 (or
alternatively activated) phenotype that is associated with the pro-
duction of anti-inflammatory mediators. In contrast, M1 (classi-
cally activated) macrophages are generated by proinflammatory
cytokines and TLR ligands, such as LPS. One of the main products
of M2 macrophages is arginase 1. This enzyme converts arginine
into ornithine, which is a precursor of polyamines and collagen, in
turn contributing to extracellular matrix generation. Thus, one of
the main functions of alternatively activated macrophages is be-
lieved to be tissue repair, and for this reason these cells are also
called wound-healing macrophages (59).
Type I ROP16 is a potent inducer of arginase 1, consistent with
a specific role of ROP16 in sustained activation of STAT6 (8). In
fact, an interesting antagonistic relationship has been proposed in
which type I and type III parasites trigger ROP16-dependent and
STAT6-dependent M2 activation, whereas type II parasites induce
GRA15-dependent and NF-B-dependent M1 activation (36).
Two biologically opposing outcomes are possible following in-
duction of arginase 1 in infected cells. On the one hand, Toxo-
plasma is a polyamine auxotroph; therefore, induction of arginase
1 could promote growth of type 1 parasites by supplying essential
polyamine nutrients, as is seen in some cases (15, 36). Alterna-
tively, the parasite is also an arginine auxotroph, and therefore
induction of arginase 1 could act to limit growth of parasites by
limiting the availability of this essential amino acid, which is also
seen in some cases (8, 25). Possibly, use of different host cell types
or amounts of arginine available underlies these disparate results.
During in vivo infection, ROP16 knockout parasites display a
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growth advantage over ROP16 competent parasites that depends
on ROP16-dependent and STAT6-dependent host cell expression
of arginase 1. The in vivo growth advantage observed in ROP16
knockout parasites suggests that arginine availability can become
limiting during infection (8). Parasite control of host signaling
pathways can regulate nutrient availability, perhaps allowing the
parasite to regulate its own growth rate. This is a particularly in-
teresting nutritional adaptation for ROP16, because Toxoplasma
is unusual in lacking metabolic pathways for either synthesis of
arginine (25), or for the degradation of this amino acid via a
parasite-encoded arginase (24).
ROP16-mediated STAT6 activation and induction of arginase
1 may also decrease the availability of arginine as a substrate for
inducible nitric oxide synthase (iNOS). Therefore, in addition to
the potential of ROP16 to reduce arginine availability for parasite
growth, ROP16 may also enhance parasite survival by decreasing
the production of nitric oxide (NO). While iNOS and NO do not
appear to be essential for the control of acute infection, these host
responses are necessary for the control of chronic infection (72).
Additional functions for parasite-induced STAT6 activation
are also possible. The chemokines CCL17 and CCL22 (whose re-
ceptor is CCR4) are strongly upregulated in macrophages infected
with type I but not type II T. gondii (44). The ccl17 gene is known
to possess functional STAT6 binding sites, and it therefore seems
likely that this chemokine is under the control of type I ROP16
(47, 87). Studies in Ccr4/ mice suggest that this receptor and its
chemokine ligands are involved in several aspects of innate immu-
nity as well as in Th2-type adaptive immunity (60). It remains to
be determined if ROP16-mediated induction of these chemokines
plays a role in disease pathogenesis or initiation of immunity
in vivo.
UNDERSTANDING ROP16 AND IN VIVO STAT3 AND STAT6
ACTIVATION
Studies on the function of ROP16 are revealing the complexity of
this rhoptry molecule in the host-parasite interaction. STAT3-
driven activation by type I ROP16 plays a role in downregulating
inflammatory cytokines, an effect that is apparent in vivo as de-
creased IL-12 responses (8, 10). For the parasite, this could be a
means to prevent or delay immune recognition and elimination.
We found that mouse astrocytes and microglial cells produce mi-
crobicidal nitric oxide (NO) following IFN- activation but that
this response was suppressed by Toxoplasma in a ROP16-
dependent manner (8). The finding that ROP16 knockout para-
sites do not persist in activated astrocytes coupled with older re-
ports showing that NO is an important defense mechanism
against T. gondii in the brain suggests that ROP16-dependent
STAT3 activation is a way to promote parasite persistence during
chronic infection (27, 72). Alternatively, ROP16-dependent
downregulation of proinflammatory responses could be a means
to avoid proinflammatory cytokine pathology during infection. It
is well known that Toxoplasma can cause lethal Th1 cytokine over-
production dependent on the host genotype and parasite dose (30,
49). This is not a desired outcome for the parasite, which seeks to
establish latent infection to maximize chances of transmission to a
new host. ROP16 could function to dampen down the inflamma-
tory response enough to avoid pathology without leading to un-
controlled parasite replication and host death.
Evidence for an anti-inflammatory function for type I ROP16
comes from models of oral infection. High-dose type II Toxo-
plasma infection of C57BL/6 mice results in lesions in the small
intestine mediated by overproduction of IL-12, TNF-, and
IFN- (48, 49). The parasite seems to act as a trigger, causing tissue
damage, emergence of enteroadhesive Escherichia coli, and bacte-
rial subepithelial translocation culminating in fulminant pathol-
ogy (33, 34). However, type II parasites expressing type I ROP16
appear to cause less inflammation in the intestine (36). This might
be seen as evidence for an anti-inflammatory effect of type I
ROP16, but it is also possible that this is due to type I ROP16-
dependent limitation in parasite replication.
An important role for ROP16 may be its capacity to influence
nutrient acquisition by Toxoplasma. The parasite relies on the host
for many nutrients, including amino acids and nucleic acid pre-
cursors. In particular, arginine is an essential amino acid that T.
gondii must scavenge from the host cell (25). Limiting arginine
availability through increased arginase 1 expression could be a
host’s defense response to limit infection. Alternatively, by limit-
ing parasite replication, ROP16-driven STAT6-dependent argi-
nase 1 induction could allow cells to carry parasites longer, effec-
tively functioning as Trojan horses to spread infection. Yet, it has
also been proposed that induction of arginase 1 could have the
opposite effect, promoting production of polyamines that the par-
asite also requires for survival (36). In this respect, ROP16 might
function to increase parasite dissemination by promoting in-
creased cycles of infection and lysis. However, the observation that
type I ROP16-null parasites expand more rapidly in vivo tends to
argue against this (8).
We do not fully understand the role of ROP16 during infec-
tion, but clearly the biology of this rhoptry kinase is complex (Fig.
1). ROP16 appears to be a central regulator of the host-parasite
interaction that controls inflammatory cytokine production, sup-
pression of TLR and IFN- responses in infected cells, and nutri-
ent availability that determines both parasite growth rate and host
ability to produce nitric oxide. This complexity is not surprising
given that ROP16 activates (at least) two distinct transcription
factors with their own independent activities. Determining
whether ROP16 mediates its effects through STAT3 or STAT6 in
vivo is complicated by the lethality of global STAT3 knockout, as
well as bystander STAT activation due to the parasite-induced
cytokine response. The predominant activity of ROP16 may de-
pend on the cell type hosting the parasite, amount of arginine
available in the host microenvironment, or on the parasite life
cycle stage. The concept that a single rhoptry molecule may have
multiple distinct functions has recent precedent, inasmuch as
rhoptry kinase ROP18 deactivates IRG proteins to prevent de-
struction of the PVM while at the same time targeting transcrip-
tion factor ATF6 for proteasomal degradation that affects DC
antigen presentation to CD8 T lymphocytes (23, 79, 88). The
multifunctional activities of these secreted parasite effector mole-
cules that function within infected cells provide new challenges to
understanding their functions in cells and animals.
PROTOZOAN TYROSINE KINASES—EVOLUTIONARY
CONSIDERATIONS
Protein tyrosine kinases are an evolutionary innovation that ac-
companied emergence of multicellular organisms. They function
to create high-affinity binding sites for proteins containing Src
homology-2 (SH2) domains, and they are regulated by protein
tyrosine phosphatases. With the exception of choanoflagellates
(which are believed to be the most closely related of unicellular
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organisms to metazoans), there are few recognizable tyrosine ki-
nases, protein tyrosine phosphatases, or SH2 domain-containing
proteins in the protozoa (54, 55, 64). Then how is it that ROP16
can be a tyrosine kinase for this signaling module? ROP16 was
originally identified as a putative serine-threonine kinase, mole-
cules that are abundant throughout evolution (53). There is evi-
dence in some fungi that serine-threonine kinases can also medi-
ate inefficient tyrosine phosphorylation (64). The function of
ROP16 would be consistent with a view that this was originally a
functional serine-threonine kinase that acquired tyrosine kinase
activity. It is therefore possible that ROP16 is a promiscuous ki-
nase, maintaining functional serine-threonine activity on still-to-
be-discovered host or parasite protein targets while also maintain-
ing functional tyrosine kinase activity on host STAT3 and STAT6
signaling cascades. The unusual adaptation of ROP16 into a func-
tional tyrosine kinase in mammalian cells suggests that ROP16 is
important for the successful global expansion of this parasite.
FUTURE DIRECTIONS
Research on T. gondii is leading the way in our understanding of
how intracellular eukaryotes manipulate the invaded host cell, but
the field is still in its infancy. The consequences of ROP16 intra-
cellular injection in other host species, such as humans and cats
(the definitive host), are not yet known. We do not completely
understand how ROP16 affects the mucosal immune response
during initiation of infection, nor do we know if this molecule
plays a role during establishment of chronic infection or during
toxoplasmic encephalitis. Because of the promiscuous nature of T.
gondii, the consequences of ROP16-mediated STAT activation
need to be considered in other cells that the parasite invades. It has
been estimated based on phylogenomic analysis that there are at
least 44 rhoptry kinase family genes (62). We understand some-
thing of the function of two (ROP16, ROP18). The functions of
ROP5 and ROP38 kinases, in particular, can be expected to be
revealed in the near future. It seems certain that other important
rhoptry molecules that interact with the host cell await discovery.
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